Incyte announces additional results from ruxolitinib Phase III trial on myelofibrosis

Links shared publicly online about this topic.

222
total visits

Incyte announces additional results from ruxolitinib Phase III trial on myelofibrosis

Incyte Corporation announced today additional symptom improvement and quality of life (QoL) results from COMFORT-I, a randomized, double-blinded, placebo-controlled Phase III trial of Incyte's JAK1 and JAK2 inhibitor, ruxolitinib, in patients with myelofibrosis (MF).

View full resource at news-medical.net

Tags: Oncology, News